


ATAGI recommended COVID-19 vaccine doses¹



For individuals without risk factors²




Notes:

1. Monovalent Omicron XBB.1.5 vaccines are preferred; for ages in which a monovalent XBB.1.5-containing vaccine is not approved, [use a vaccine approved for that age group](#).
2. Includes those with a medical condition that increases the risk of severe COVID-19 illness (refer to [Australian Immunisation Handbook](#)) or those with disability with significant or complex health needs or multiple comorbidities which increase the risk of poor outcomes from COVID-19.
3. 2023 booster (or additional) dose(s) should be given to eligible individuals from 6 months after their last dose or infection; however where previous infection details are unknown, it is appropriate to proceed with the dose. A person may be vaccinated earlier in exceptional circumstances, such as before starting an immunosuppressant, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).
4. Consider a booster (or additional) dose based on an individual risk benefit assessment with an immunisation provider.

ATAGI recommended COVID-19 vaccine doses¹



For individuals with risk factors²



Notes:

1. Monovalent Omicron XBB.1.5 vaccines are preferred; for ages in which a monovalent XBB.1.5-containing vaccine is not approved, [use a vaccine approved for that age group](#).
2. Includes those with a medical condition that increases the risk of severe COVID-19 illness (refer to [Australian Immunisation Handbook](#)) or those with disability with significant or complex health needs or multiple comorbidities which increase the risk of poor outcomes from COVID-19.
3. A third primary dose is recommended for all people aged 6 months or older with [severe immunocompromise](#) who are receiving a 2-dose primary course.
4. 2023 booster (or additional) dose(s) should be given to eligible individuals from 6 months after their last dose or infection; however where previous infection details are unknown, it is appropriate to proceed with the dose. A person may be vaccinated earlier in exceptional circumstances, such as before starting an immunosuppressant, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).
5. Consider a booster (or additional) dose based on an individual risk benefit assessment with an immunisation provider.
6. If severely immunocompromised only. Refer to [ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised](#).